Tatsuya Atsumi, Tien-Tsai Cheng, Tuyen Do Gia, Shunsuke Furuta, Harold Michael P. Gomez, Llewellyn T. Hao, Ngoc Phuong Thao Huynh, Michihito Kono, Sandra Navarra, Kajohnsak Noppakun, Kenji Oku, Bernadette Reyes, Bancha Satirapoj: Long-term Safety and Efficacy of Voclosporin in Asian Patients with Lupus Nephritis. APLAR. 2022.
Menn-Josephy H, Palmen M, Truman M, Leher H: Efficacy and Safety of Voclosporin Over Three Years in Patients with Severe Lupus Nephritis. J Am Soc Nephrol 33, 2022: Page 33.
Link: 2022 ASN Abstract
Tagoe KJ, Orujov E, Baker MG, Cipolla L, McLemore J, Leher H: Enlight-LN: A Prospective Observational Registry of Patients Treated with Voclosporin for Lupus Nephritis in the United States. J Am Soc Nephrol 33, 2022.
Link: 2022 ASN Abstract
Caster D, Saxena A, Almaani S, Rosales A, Leher H: Long-term Use of Voclosporin in Patients with Class V Lupus Nephritis: Results from the AURORA 2 Continuation Study. J Am Soc Nephrol 33, 2022: Page 498.
Link: 2022 ASN Abstract
Parikh S, Arriens C, Hodge L, Mela C, Leher H: Voclosporin for Lupus Nephritis: Assessment of Long-Term Safety and Efficacy Including Renal Outcome Over Three Years of Treatment in the Phase 3 AURORA 1 and AURORA 2 Studies. J Am Soc Nephrol 33, 2022: Page 184.
Link: 2022 ASN Abstract
Saxena R, Collins C, Birardi V, Pavlova-Wolf A: Long-Term Safety And Efficacy Of Voclosporin In Patients With Lupus Nephritis and Low eGFR. J Am Soc Nephrol 33, 2022: Page 184.
Link: 2022 ASN Abstract
Afshinnia F, Rehaume LM, Cross JL, Huizinga RB, Pennathur S: Voclosporin Therapy Induces Systemic Lipidomic Alterations: Implications for Lipid Mediators for Remission of Lupus Nephritis. J Am Soc Nephrol 33, 2022: Page 792.
Link: 2022 ASN Abstract
Morales S, Cross J, Huizinga R. AUR200: An Improved BAFF/APRIL Inhibitor with Increased Potency and Safety for the Treatment of B Cell-Mediated Diseases [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9).
Link: 2022 ACR Abstract
Askanase A, Hodge L, Birardi V, Leher H. EARLY REDUCTIONS IN PROTEINURIA WITH VOCLOSPORIN TREATMENT ACROSS LUPUS NEPHRITIS BIOPSY CLASSES: POOLED DATA FROM THE AURA-LV AND AURORA1 TRIALS. NDT Volume 37 Supplement 1 – Abstracts Book. 2022.
Link here.
Ginzler E, Saxena A, Bal V, Birardi V, Leher H. Long-term Safety and Efficacy of Voclosporin in Hispanic and Latino Patients with Lupus Nephritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9).
Link: 2022 ACR Abstract
Slawny N, Pavlova-Wolf A, Collins C, Gluck R, Hodge L, Leher H. Enlight-LN: A Prospective Observational Registry of Patients Treated with Voclosporin for Lupus Nephritis in the United States. CCR West, San Diego, California, October 20 – 23, 2022.
Anders HJ, Federico R, Randhawa S, Leher H. Voclosporin is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations. Annals of the Rheumatic Diseases 2022;81:325.
Link: 2022 EULAR Abstract
Saxena A, Teng YKO, Collins C, England N, Leher H. Voclosporin for Lupus Nephritis: Results of the Two-year AURORA 2 Continuation Study. Annals of the Rheumatic Diseases 2022;81:325.
Link: 2022 EULAR Abstract
Teng YKO, Saxena A, Palmen M, Birardi V, and Lisk L. VOCLOSPORIN FOR LUPUS NEPHRITIS: RESULTS OF THE TWO-YEAR AURORA 2 CONTINUATION STUDY. NDT Volume 37 Supplement 1 – Abstracts Book. 2022.
Menn-Josephy H, Truman M, Palmen M, Mina-Osorio P: Voclosporin is Effective in Achieving Complete Renal Response in Severe Lupus Nephritis [SA-OR31]. J Am Soc Nephrol 32, 2021:48.
Link: 2021 ASN Abstract
Mina-Osorio P, Dahl K, Collins C, Gluck R, Leher H. ENLIGHT-LN: A Prospective Observational Registry of Patients Treated with Voclosporin for Lupus Nephritis in the United States. American Journal of Kidney Diseases, Volume 79, Issue 4, S10.
Link: 2022 NKF Abstract
Diamond B, Truman M, Mina-Osorio P. The Efficacy of Voclosporin in Lupus Nephritis is Independent of Changes in Anti-dsDNA and Complement at Week 52. American Journal of Kidney Diseases, Volume 79, Issue 4, S2.
Link: 2022 NKF Abstract
Jolly M, Truman M, Hodge L, Lisk L. Attainment of Complete Renal Response Results in Significant Improvements in Lupus Impact Tracker in the AURORA 1 Study of Voclosporin in Lupus Nephritis. American Journal of Kidney Diseases, Volume 79, Issue 4, S17.
Link: 2022 NKF Abstract
Rehaume LM, Cross JL, Huizinga RB. Confirmation of the immunosuppressive function of voclosporin at the clinically relevant lupus nephritis dose in lupus-prone mice. American Journal of Kidney Diseases, Volume 79, Issue 4, S41.
Link: 2022 NKF Abstract
Ardoin S, Smoyer W, Cross JL, Hodge L, Leher H. POS-227 LIPID PROFILES OF PATIENTS WITH LUPUS NEPHRITIS IN THE VOCLOSPORIN AURA-LV AND AURORA 1 CLINICAL TRIALS. Kidney International Reports Vol. 7. Issue 2, Supplement S99. Published in issue: February 2022.
Link here.
Palmer B, Tumlin J, Radhakrishnan J, Rehaume LM, Huizinga RB. POS-390 ELECTROLYTE PROFILES OF LUPUS NEPHRITIS PATIENTS TREATED WITH THE NOVEL CALCINEURIN INHIBITOR VOCLOSPORIN. Kidney International Reports Vol. 7. Issue 2, Supplement S175–S176. Published in issue: February 2022.
Link here.
Radhakrishnan J, Palmer B, Tumlin J, Cross JL, Huizinga RB. POS-391 LUPUS NEPHRITIS PATIENTS TREATED WITH VOCLOSPORIN DO NOT SHOW AN INCREASE IN URINARY KIDNEY INJURY AND PRO-FIBROTIC BIOMARKERS. Kidney International Reports Vol. 7. Issue 2, Supplement S176–S177. Published in issue: February 2022.
Link here.
